Multi-Cancer Early Detection Market Set for Explosive Growth to US$ 32.75 Billion by 2035, Led by North America's 37.6% Market Share | Key Players - GRAIL Inc., Guardant Health Inc., Exact Sciences Corporation

The Multi Cancer Early Detection (MCED) Market was valued at US$ 4.72 billion in 2025 and is projected to reach US$ 32.75 billion by 2035, growing at a CAGR of 20.88% during the forecast period (2026 to 2035).

The market is experiencing rapid growth as healthcare systems increasingly emphasize early cancer detection to improve survival outcomes, reduce treatment costs, and support precision medicine initiatives. Rising investments in liquid biopsy technologies, advances in genomic sequencing, and growing awareness of preventive oncology are accelerating the adoption of MCED tests across clinical and research settings.

Industry participants are focusing on developing highly sensitive, blood-based multi-cancer screening solutions supported by artificial intelligence, next-generation sequencing, and biomarker discovery to enhance diagnostic accuracy and expand clinical utility. Companies establishing strong clinical validation, regulatory approvals, and strategic collaborations with healthcare providers and research institutions are expected to strengthen their competitive position as demand for population-scale cancer screening continues to grow.

Get a Free Sample PDF of this Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/multi-cancer-early-detection-market?ram

Key Industry Developments

United States
✅ January 2026: GRAIL, Inc. submitted the final Premarket Approval (PMA) application to the U.S. FDA for its Galleri® Multi-Cancer Early Detection (MCED) blood test, marking a major regulatory milestone toward broader clinical adoption in the U.S. The submission supports commercialization of Galleri as an FDA-approved screening test capable of detecting signals from more than 50 cancer types through a single blood sample.

✅ October 2025: GRAIL, Inc. announced positive PATHFINDER 2 registrational study results demonstrating that the Galleri® MCED test increased cancer detection more than seven-fold when used alongside recommended USPSTF cancer screenings. More than half of the cancers detected were early-stage, while approximately three-quarters were cancers lacking existing routine screening options, reinforcing the technology's clinical value.

✅ October 2025: GRAIL, Inc. entered a strategic collaboration with Samsung C&T and Samsung Electronics to accelerate commercialization of the Galleri® MCED test across Asia, with potential expansion into Japan. The agreement included strategic investment and highlighted growing international deployment of advanced multi-cancer early detection technologies developed in the United States.

Japan:
✅ July 2026: Abbott Japan officially launched Cancerguard®, its multi-cancer early detection (MCED) blood test, making Japan the first market outside the United States to commercially offer the company's MCED technology. The blood-based test analyzes biomarkers associated with more than 50 cancer types through a single blood draw and is being introduced via affiliated healthcare institutions.

✅ March 2026: Abbott Japan announced plans to introduce Cancerguard® in Japan during July 2026, expanding access to advanced methylation DNA- and protein-based MCED screening technology. The company highlighted the test's ability to complement existing national screening programs by targeting cancers that currently lack routine screening methods.

✅ October 2025: Samsung C&T, in collaboration with GRAIL, Inc., announced plans to commercialize the Galleri® MCED blood test across key Asian markets, including potential future expansion into Japan. The partnership represents an important step toward introducing advanced U.S.-developed multi-cancer early detection technologies into the Japanese healthcare market.

Strategic Acquisitions & Partnerships
✅ Freenome - Strategic Partnership (Artificial Intelligence Collaboration with NVIDIA)
January, 2026
Freenome announced a strategic collaboration with NVIDIA to accelerate the development of its AI-powered multi-cancer early detection platform. The partnership leverages NVIDIA's accelerated computing and deep learning technologies to improve analysis of cell-free DNA signals and support the development of personalized blood-based multi-cancer screening tests.

✅ Freenome - Strategic Partnership (International Commercialization Agreement with Roche)
November, 2025
Freenome expanded its collaboration with Roche through an exclusive agreement granting Roche ex-U.S. rights to develop and commercialize Freenome's blood-based cancer screening technologies in decentralized ("kitted") formats. Roche also committed additional equity investment and R&D support to accelerate global adoption of early cancer detection technologies.

Key Players:
GRAIL Inc. | Guardant Health Inc. | Exact Sciences Corporation | Freenome Holdings Inc. | Burning Rock Dx | Singlera Genomics Inc. | SeekIn Inc. | Illumina Inc. | Foundation Medicine Inc. | Natera Inc.

Key Highlights: Top 5 Key Players in Multi-Cancer Early Detection Market 2026
-GRAIL Inc.: Advanced the Galleri® Multi-Cancer Early Detection (MCED) Test by submitting its FDA Premarket Approval (PMA) application and expanding integration with Epic electronic health records. The company also presented PATHFINDER 2 and NHS-Galleri trial data demonstrating improved detection of multiple cancers at earlier stages and reduced late-stage diagnoses.

-Guardant Health Inc.: Expanded the ShieldTM Multi-Cancer Detection (MCD) Test into Asia through a strategic partnership with Manulife, broadening access across Hong Kong, Singapore, and the Philippines. The methylation-based blood test enables detection of multiple cancer types from a single blood sample for average-risk adults.

-Exact Sciences Corporation: Commercialized the CancerguardTM Multi-Cancer Early Detection Blood Test, the first commercially available MCED test combining multiple biomarker classes to improve early cancer detection. The company further strengthened the platform with ongoing clinical data presentations and continued development of its multi-cancer screening portfolio.

-Freenome Holdings Inc.: Expanded its blood-based cancer screening portfolio with SimpleScreen CRC, an AI-enabled, multiomics blood test for colorectal cancer that received FDA approval in 2026. The launch strengthens Freenome's liquid biopsy capabilities and supports broader adoption of minimally invasive early cancer screening technologies.

-Illumina Inc.: Continued to strengthen the MCED ecosystem by advancing next-generation sequencing (NGS) technologies that support highly sensitive circulating tumor DNA (ctDNA) and methylation-based assays. Illumina's sequencing platforms remain foundational for the development and clinical deployment of multi-cancer early detection tests by leading diagnostics companies.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/multi-cancer-early-detection-market?ram

Main Drivers and Trends Shaping the Future of the Multi-Cancer Early Detection Market
-Rising Focus on Early Cancer Detection: Growing emphasis on identifying multiple cancers at earlier stages through a single blood test is driving demand, as earlier diagnosis can improve treatment outcomes and reduce cancer-related mortality.

-Advancements in Liquid Biopsy and Genomics: Rapid progress in cell-free DNA (cfDNA) analysis, next-generation sequencing (NGS), methylation profiling, and artificial intelligence is improving the accuracy and clinical utility of multi-cancer early detection (MCED) tests.

-Expanding Precision Medicine Initiatives: Increasing investments in precision oncology and population-based cancer screening programs are encouraging the integration of MCED technologies into preventive healthcare and personalized treatment pathways.

-Growing Clinical Validation and Industry Collaborations: Large-scale clinical studies, strategic partnerships among diagnostics companies, healthcare providers, and research institutions are accelerating technology validation, regulatory engagement, and commercialization efforts.

-Market Hurdles: High testing costs, the need for extensive clinical evidence, reimbursement uncertainties, regulatory approval challenges, and concerns regarding false-positive or false-negative results remain key barriers to broader market adoption.

Regional Insights:
-North America: 37.6% (Largest share, driven by advanced molecular diagnostics infrastructure, widespread adoption of liquid biopsy technologies, strong precision medicine investments, and the presence of leading MCED developers such as GRAIL, Guardant Health, and Exact Sciences.)

-Europe: 28.5% (Supported by government-funded cancer screening initiatives, strong healthcare reimbursement systems, increasing adoption of next-generation sequencing, and growing investments in precision oncology.)

-Asia-Pacific: 24.1% (Fastest-growing region, fueled by rising cancer incidence, expanding genomic medicine programs, improving healthcare infrastructure, and increasing investments in early cancer screening across China, Japan, India, and South Korea.)

-Latin America: 5.8% (Growth supported by improving access to advanced diagnostics, expanding oncology care infrastructure, and increasing awareness of early cancer detection in Brazil, Mexico, and Argentina.)

-Middle East & Africa: 4.0% (Emerging market driven by expanding cancer care infrastructure, increasing government healthcare investments, and gradual adoption of precision diagnostic technologies in GCC countries, South Africa, and Israel.)

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=multi-cancer-early-detection-market?ram

Market Segmentation Analysis:
-By Test Type: Blood-Based MCED Tests Lead Clinical Development
Blood-based multi-cancer early detection (MCED) tests represent the primary segment, offering minimally invasive screening through analysis of circulating tumor DNA (ctDNA), methylation patterns, and other circulating biomarkers. Their ability to detect multiple cancers from a single blood draw supports growing clinical adoption and ongoing validation studies. Other emerging approaches, including urine- and saliva-based tests, are under investigation for specific cancer detection applications but remain at earlier stages of commercialization and clinical validation.

-By Technology: Next-Generation Sequencing Dominates Innovation
Next-generation sequencing (NGS) is the leading technology, enabling comprehensive analysis of circulating tumor DNA, methylation signatures, and genomic alterations with high sensitivity. Methylation analysis has become a key advancement for identifying tissue of origin and improving early-stage cancer detection. Complementary technologies such as PCR, artificial intelligence-enabled bioinformatics, and multi-omics platforms further enhance test accuracy, data interpretation, and clinical utility.

-By Sample Type: Blood Samples Remain the Preferred Choice
Blood samples dominate the market due to their minimally invasive nature, ease of collection, and compatibility with liquid biopsy technologies. Blood-based assays allow simultaneous detection of multiple cancer-associated biomarkers, making them the preferred option for MCED testing. Other sample types, including urine, saliva, and tissue specimens, are being explored for specific clinical applications but currently have more limited use in broad multi-cancer screening.

-By Cancer Type: Multiple Solid Tumors Drive Demand
MCED tests are primarily designed to detect multiple solid tumors from a single sample, including lung, breast, colorectal, prostate, ovarian, pancreatic, and liver cancers. Strong emphasis is placed on identifying aggressive cancers that currently lack routine screening methods. Expanding biomarker research continues to improve the ability to detect a broader range of malignancies at earlier, more treatable stages.

-By End User: Hospitals and Diagnostic Laboratories Lead Adoption
Hospitals and diagnostic laboratories are the primary end users, supported by advanced molecular testing infrastructure, specialized pathology services, and participation in clinical research programs. Academic and cancer research institutes play a vital role in validating MCED technologies through large-scale studies. Specialized oncology centers are also expanding adoption as precision oncology and early cancer detection initiatives continue to grow.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicated reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.